News

Biognosys Launches Groundbreaking P2 Plasma Enrichment Technology for Unbiased, Deep Plasma Proteomics at ASMS 2024

ZURICH, Switzerland and NEWTON, Massachusetts, May 30, 2024 — GlobeNewswire — Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible,...

read more

CUTISS announces first closing of CHF 25M in Series C funding round

Switzerland, 17 May 2024 – CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, is glad to announce the first closing of CHF 25 million in its Series C funding round. This milestone demonstrates strong investor confidence in CUTISS’ mission and progress. The Series...

read more

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or...

read more

InSphero Secures Exclusive Commercialization Partnership with Genome Biologics for 3D Cardiac Organoid Platform

May 15, 2024, Zürich, Switzerland and Frankfurt, Germany In a significant expansion of its industry-leading portfolio, InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany. This partnership will grant InSphero exclusive global rights to commercialize Genome Biologics' revolutionary 3D Cardiac Organoid Platform. This platform...

read more